Molecular Imaging of Pituitary Pathology.

2区医学 Q2 Medicine

Frontiers of Hormone Research Pub Date : 2016-03-15 DOI:10.1159/000442329

Wouter W de Herder

引用次数: 2

Abstract

The presence of large numbers and/or the high affinity of dopamine D2 and/or somatostatin receptors on pituitary adenomas may enable their visualization with radionuclide-coupled receptor agonists or antagonists. However, the role of these imaging modalities in the differential diagnosis of or therapeutic purposes for pituitary lesions is very limited. Only in very specific cases might these molecular imaging techniques become helpful. These include the differential diagnosis of pituitary lesions, ectopic production of pituitary hormones, such as adrenocorticotrophic hormone, growth hormone (GH) or their releasing hormones (corticotropin-releasing hormone and GH-releasing hormone), and the localization of metastases from pituitary carcinomas.

查看原文本刊更多论文

垂体病理分子成像。

多巴胺D2和/或生长抑素受体在垂体腺瘤上大量和/或高亲和力的存在，可能使放射性核素偶联受体激动剂或拮抗剂能够显示它们。然而，这些成像方式在垂体病变的鉴别诊断或治疗目的中的作用非常有限。只有在非常特殊的情况下，这些分子成像技术才会有用。这些包括垂体病变的鉴别诊断，垂体激素的异位分泌，如促肾上腺皮质激素、生长激素(GH)或其释放激素(促肾上腺皮质激素释放激素和GH释放激素)，以及垂体癌转移灶的定位。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers of Hormone Research 医学-内分泌学与代谢

自引率

0.00%

发文量

期刊介绍： A series of integrated overviews on cutting-edge topics New sophisticated technologies and methodological approaches in diagnostics and therapeutics have led to significant improvements in identifying and characterizing an increasing number of medical conditions, which is particularly true for all aspects of endocrine and metabolic dysfunctions. Novel insights in endocrine physiology and pathophysiology allow for new perspectives in clinical management and thus lead to the development of molecular, personalized treatments. In view of this, the active interplay between basic scientists and clinicians has become fundamental, both to provide patients with the most appropriate care and to advance future research.